Cargando…

Efficacy of everolimus‐based therapy in advanced triple‐positive breast cancer: Experience from three cancer centers in China

BACKGROUND: Triple‐positive breast cancer (TPBC) is highly invasive and lacks well‐established treatment strategies, especially in patients with advanced stage disease. This study aimed to explore the efficacy of everolimus in patients with metastatic TPBC (mTPBC) in a multicenter real‐world setting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Yujing, Jiang, Hanfang, Ma, Fei, Wang, Jiayu, Zhang, Pin, Li, Qing, Tian, Xinzhu, Xu, Binghe, Zhao, Weihong, Fan, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693944/ https://www.ncbi.nlm.nih.gov/pubmed/37936567 http://dx.doi.org/10.1111/1759-7714.15133

Ejemplares similares

Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer
por: Fan, Ying, et al.
Publicado: (2015)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice
por: Xiu, Meng, et al.
Publicado: (2022)

Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2021)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts
por: Mercatali, Laura, et al.
Publicado: (2016)

SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer
por: Zhu, Anjie, et al.
Publicado: (2016)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
por: Wang, Jiayu, et al.
Publicado: (2023)

SHOC2 mediates the drug-resistance of triple-negative breast cancer cells to everolimus
por: Geng, Wenwen, et al.
Publicado: (2023)

There Is No Association between MicroRNA Gene Polymorphisms and Risk of Triple Negative Breast Cancer in a Chinese Han Population
por: Ma, Fei, et al.
Publicado: (2013)

Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis
por: Zhang, Jingyi, et al.
Publicado: (2020)

Genetic polymorphisms of autophagy-related gene 5 (ATG5) rs473543 predict different disease-free survivals of triple-negative breast cancer patients receiving anthracycline- and/or taxane-based adjuvant chemotherapy
por: Li, Meiying, et al.
Publicado: (2018)

In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China
por: Li, Yiqun, et al.
Publicado: (2022)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
por: Singh, Jasmeet Chadha, et al.
Publicado: (2014)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis
por: Han, Yiqun, et al.
Publicado: (2022)

Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients
por: Guo, Jihong, et al.
Publicado: (2019)

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node–Positive Breast Cancer: A Randomized Clinical Trial
por: Yuan, Peng, et al.
Publicado: (2023)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies
por: Guan, Xiuwen, et al.
Publicado: (2023)

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
por: Paplomata, Elisavet, et al.
Publicado: (2013)

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
por: He, Maiyue, et al.
Publicado: (2023)

Phase I/II clinical trial of everolimus combined with gemcitabine/cisplatin for metastatic triple-negative breast cancer
por: Park, In Hae, et al.
Publicado: (2018)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Formononetin Enhances the Tumoricidal Effect of Everolimus in Breast Cancer MDA-MB-468 Cells by Suppressing the mTOR Pathway
por: Zhou, Qianmei, et al.
Publicado: (2019)

Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China
por: Lin, Shaoyan, et al.
Publicado: (2020)

Everolimus in the Treatment of Metastatic Breast Cancer
por: Royce, Melanie E, et al.
Publicado: (2015)

The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study
por: Han, Yiqun, et al.
Publicado: (2022)

Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer
por: Wang, Jiayu, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8em5j9ju2o4od79u3afm7j0vf2